Development of the new cell therapy for GVHD using tolerogenic dendtiric cells treated by PUVA treatment
Project/Area Number |
26461604
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | Department of Clinical Research, National Hospital Organization Kanazawa Medical Center |
Principal Investigator |
Maeba Hideaki 独立行政法人国立病院機構(金沢医療センター臨床研究部), その他部局等, その他 (10419335)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 制御性樹状細胞 / PUVA / GVHD / 移植片対宿主病 |
Outline of Final Research Achievements |
Bone marrow-derived cultured DCs acquired tolerogenicity by PUVA (psoralen+UVA) treatment in mice. In vitro assays, strong tolerogenicity was observed when adding PUVA-DC even from third party strain into MLR. That is, the PUVA-DC have tolerogenic function in a MHC-independent manner. We showed that cell-to-cell contact was needed to mediate the regulatory effect by transwell experiment. Next, we compared the expression of the IDO, which induces T-cell anergy, by real-time PCR between PUVA-DC and BM-DC. An increase IDO gene transcription level was observed in PUVA-DC about 5 times more than in BM-DC. But adding 1-MT, which is an inhibitor of IDO, had no effects on MLR with PUVA-DC. We transfused PUVA-DC (Host-type, Donor-type, Third-party-type) in a mouse GVHD model, but the GVHD inhibitory effects were not observed. It was thought the survival of PUVA-DC was insufficient. These data leads us to search for technique to make PUVA-DC to survive after in vivo administration.
|
Report
(4 results)
Research Products
(11 results)
-
[Journal Article] Pathognomonic serum cytokine profiles identify life-threatening langerhans cell histiocytosis2017
Author(s)
Ikawa Y, Nishimura R, Araki R, Noguchi K, Muraoka M, Fukuda M, Fujiki T, Kuroda R, Mase S, Maeba H, Nomura K, Yachie A
-
Journal Title
British journal of hematology
Volume: 176(3)
Issue: 3
Pages: 495-497
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
[Journal Article] シクロスポリンA(CyA)の内服方法の変更で寛解に至ったネフローゼ症候群の1例2014
Author(s)
井上 なつみ, 山宮 麻里, 田崎 優子, 石川 さやか, 篠崎 絵里, 上野 和之, 横山 忠史, 前田 文恵, 千田 裕美, 井上 巳香, 清水 正樹, 前馬 秀昭, 酒詰 忍, 太田 和秀
-
Journal Title
日本小児腎臓病学会雑誌
Volume: 27
Pages: 137-140
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] 二相性けいれんとMRIでの拡散能低下を呈したRSウイルス脳症の1例2014
Author(s)
千田 裕美, 村岡 正裕, 山宮 麻里, 井上 なつみ, 木場 由希子, 篠崎 絵里, 前田 文恵, 水野 和徳, 井上 巳香, 前馬 秀昭, 酒詰 忍, 太田 和秀, 谷内江 昭宏, 河島 尚志
-
Journal Title
小児感染免疫
Volume: 26
Pages: 241-246
Related Report
Peer Reviewed / Open Access
-
-
[Presentation] Frequently observed long-lasting abnormal serological tests against cytomegalovirus after allogenic hematological transplantation2016
Author(s)
Hideaki Maeba, Rie Kuroda, Toshihiro Fujiki, Kazuhiro Noguchi, Masaki Fukuda, Shintaro Mase, Raita Araki, Yasuhiro Ikawa, Shoichi Koizumi, Akihiro Yachie and Ryosei Nishimura
Organizer
BMT Tandem meeting
Place of Presentation
Honolulu, Hawaii
Year and Date
2016-02-18
Related Report
Int'l Joint Research
-
-